论文部分内容阅读
Objective Immunotherapy,principally represented by programmed death-1/programmed death ligand-1(PD-1/PD-L1)inhibitors,has improved the clinical outcome of advanced non-small cell lung cancer(NSCLC).PD-L1 profiles of tumor samples are used to select candidates for immune checkpoint inhibitors.